Retatrutide reduces sleep apnea events in two phase 3 trials published in NEJM
See kirje on näidatud inglise keeles, kuni selle tõlge on uuendatud.
The New England Journal of Medicine published two phase 3, placebo-controlled trials of investigational retatrutide in adults with moderate-to-severe obstructive sleep apnea and a body-mass index of at least 27: TRIUMPH-1-OSA (243 participants without type 2 diabetes) and TRIUMPH-2-OSA (448 with it). At 80 weeks, the apnea-hypopnea index (breathing pauses and shallow breaths per hour of sleep) fell by 34.3 and 31.7 events per hour with the two doses in the primary analysis versus 9.9 with placebo in the first trial, and by 24.7 and 25.4 versus 10.3 in the second; an intention-to-treat analysis gave similar differences from placebo. Across doses, body weight fell by up to 22.2% and 18.5% in the two trials, versus 4.8% and 5.6% with placebo. Lilly funded the trials, gastrointestinal adverse events were the most common, and retatrutide remains unapproved.